$RHHBY News Article - New Data From Phase III HAVEN 6 Study Reinforce Favorable Safety and Efficacy Profile of Genentech's Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A https://marketwirenews.com/news-releases/new-...82436.html